Your browser doesn't support javascript.
loading
Systematic analyses of regulatory variants in DNase I hypersensitive sites identified two novel lung cancer susceptibility loci.
Dai, Juncheng; Li, Zhihua; Amos, Christopher I; Hung, Rayjean J; Tardon, Adonina; Andrew, Angeline S; Chen, Chu; Christiani, David C; Albanes, Demetrios; van der Heijden, Erik H F M; Duell, Eric J; Rennert, Gad; Mckay, James D; Yuan, Jian-Min; Field, John K; Manjer, Jonas; Grankvist, Kjell; Le Marchand, Loic; Teare, M Dawn; Schabath, Matthew B; Aldrich, Melinda C; Tsao, Ming-Sound; Lazarus, Philip; Lam, Stephen; Bojesen, Stig E; Arnold, Susanne; Wu, Xifeng; Haugen, Aage; Janout, Vladimir; Johansson, Mikael; Brhane, Yonathan; Fernandez-Somoano, Ana; Kiemeney, Lambertus A; Davies, Michael P A; Zienolddiny, Shanbeh; Hu, Zhibin; Shen, Hongbing.
Afiliación
  • Dai J; Department of Epidemiology, Center for Global Health, International Joint Research Center, School of Public Health, Nanjing Medical University, Nanjing, China.
  • Li Z; Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Jiangsu Collaborative Innovation Center of Cancer Personalized Medicine, Nanjing Medical University, Nanjing, China.
  • Amos CI; Department of Epidemiology, Center for Global Health, International Joint Research Center, School of Public Health, Nanjing Medical University, Nanjing, China.
  • Hung RJ; Department of Thoracic Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
  • Tardon A; Biomedical Data Science, Geisel School of Medicine, Dartmouth College, Hanover, NH, USA.
  • Andrew AS; Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Ontario, Canada.
  • Chen C; Division of Epidemiology, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.
  • Christiani DC; Faculty of Medicine, IUOPA, University of Oviedo and CIBERESP, Oviedo, Spain.
  • Albanes D; Norris Cotton Cancer Center, Geisel School of Medicine, Hanover, NH, USA.
  • van der Heijden EHFM; Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Duell EJ; Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
  • Rennert G; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
  • Mckay JD; Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
  • Yuan JM; Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, The Netherlands.
  • Field JK; Unit of Nutrition and Cancer, Catalan Institute of Oncology (ICO), Barcelona, Spain.
  • Manjer J; Clalit National Cancer Control Center, Carmel Medical Center, Haifa, Israel.
  • Grankvist K; International Agency for Research on Cancer (IARC), World Health Organization, Lyon, France.
  • Le Marchand L; University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA.
  • Teare MD; Roy Castle Lung Cancer Research Programme, Department of Molecular and Clinical Cancer Medicine, University of Liverpool, The William Duncan Building, Liverpool, UK.
  • Schabath MB; Unit for Breast Surgery, Department of Surgery, Lund University, Malmö, Sweden.
  • Aldrich MC; Department of Surgery, Skåne University Hospital, Malmö, Sweden.
  • Tsao MS; Department of Medical Biosciences, Umeå University, Umeå, Sweden.
  • Lazarus P; Epidemiology Program, University of Hawai'i Cancer Center, Honolulu, HI, USA.
  • Lam S; School of Health and Related Research, University of Sheffield, Sheffield, South Yorkshire, UK.
  • Bojesen SE; Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
  • Arnold S; Department of Thoracic Surgery, Division of Epidemiology, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Wu X; Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
  • Haugen A; Department of Pharmaceutical Sciences, College of Pharmacy, Washington State University, Spokane, WA, USA.
  • Janout V; British Columbia Cancer Agency, Vancouver, British Columbia, Canada.
  • Johansson M; Copenhagen General Population Study, Herlev and Gentofte Hospital, Copenhagen University Hospital, Copenhagen, Denmark.
  • Brhane Y; Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen University Hospital, Copenhagen, Denmark.
  • Fernandez-Somoano A; Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Kiemeney LA; Division of Medical Oncology Markey Cancer Center, Lexington, KY, USA.
  • Davies MPA; Department of Epidemiology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Zienolddiny S; Department of Chemical and Biological Work Environment, National Institute of Occupational Health (STAMI), Oslo, Norway.
  • Hu Z; Department of Epidemiology and Public Health, Faculty of Health Sciences, Palacky University, Olomouc, Czech Republic.
  • Shen H; Department of Radiation Sciences, Umeå University, Umeå, Sweden.
Carcinogenesis ; 40(3): 432-440, 2019 05 14.
Article en En | MEDLINE | ID: mdl-30590402
ABSTRACT
DNase I hypersensitive sites (DHS) are abundant in regulatory elements, such as promoter, enhancer and transcription factor binding sites. Many studies have revealed that disease-associated variants were concentrated in DHS-related regions. However, limited studies are available on the roles of DHS-related variants in lung cancer. In this study, we performed a large-scale case-control study with 20 871 lung cancer cases and 15 971 controls to evaluate the associations between regulatory genetic variants in DHS and lung cancer susceptibility. The expression quantitative trait loci (eQTL) analysis and pathway-enrichment analysis were performed to identify the possible target genes and pathways. In addition, we performed motif-based analysis to explore the lung-cancer-related motifs using sequence kernel association test. Two novel variants, rs186332 in 20q13.3 (C>T, odds ratio [OR] = 1.17, 95% confidence interval [95% CI] 1.10-1.24, P = 8.45 × 10-7) and rs4839323 in 1p13.2 (T>C, OR = 0.92, 95% CI 0.89-0.95, P = 1.02 × 10-6) showed significant association with lung cancer risk. The eQTL analysis suggested that these two SNPs might regulate the expression of MRGBP and SLC16A1, respectively. What's more, the expression of both MRGBP and SLC16A1 was aberrantly elevated in lung tumor tissues. The motif-based analysis identified 10 motifs related to the risk of lung cancer (P < 1.71 × 10-4). Our findings suggested that variants in DHS might modify lung cancer susceptibility through regulating the expression of surrounding genes. This study provided us a deeper insight into the roles of DHS-related genetic variants for lung cancer.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Predisposición Genética a la Enfermedad / Desoxirribonucleasa I / Neoplasias Pulmonares Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Carcinogenesis Año: 2019 Tipo del documento: Article País de afiliación: China

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Predisposición Genética a la Enfermedad / Desoxirribonucleasa I / Neoplasias Pulmonares Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Carcinogenesis Año: 2019 Tipo del documento: Article País de afiliación: China